Basilea Pharmaceutica AG
SIX:BSLN

Watchlist Manager
Basilea Pharmaceutica AG Logo
Basilea Pharmaceutica AG
SIX:BSLN
Watchlist
Price: 41.15 CHF -0.48%
Market Cap: 498.8m CHF
Have any thoughts about
Basilea Pharmaceutica AG?
Write Note

Basilea Pharmaceutica AG
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Basilea Pharmaceutica AG
Cost of Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Basilea Pharmaceutica AG
SIX:BSLN
Cost of Revenue
-CHf34.9m
CAGR 3-Years
-13%
CAGR 5-Years
-9%
CAGR 10-Years
N/A
ADC Therapeutics SA
NYSE:ADCT
Cost of Revenue
-$2.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
AC Immune SA
NASDAQ:ACIU
Cost of Revenue
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
CRISPR Therapeutics AG
NASDAQ:CRSP
Cost of Revenue
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Molecular Partners AG
SIX:MOLN
Cost of Revenue
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Kuros Biosciences AG
SIX:KURN
Cost of Revenue
-CHf11m
CAGR 3-Years
-39%
CAGR 5-Years
-119%
CAGR 10-Years
N/A
No Stocks Found

Basilea Pharmaceutica AG
Glance View

Market Cap
498.8m CHF
Industry
Biotechnology

Basilea Pharmaceutica AG engages in the development and commercialization of pharmaceutical products. The company is headquartered in Basel, Basel-Stadt and currently employs 154 full-time employees. The company went IPO on 2004-03-25. The firm operates in one segment, which is the discovery, development and commercialization of innovative pharmaceutical products to meet the needs of patients with cancer and infectious diseases. The company launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of severe bacterial infections. Additionally It is conducting clinical studies with two targeted drug candidates for the treatment of a range of cancers and have a number of preclinical assets in both cancer and infectious diseases in its portfolio.

BSLN Intrinsic Value
75.14 CHF
Undervaluation 45%
Intrinsic Value
Price

See Also

What is Basilea Pharmaceutica AG's Cost of Revenue?
Cost of Revenue
-34.9m CHF

Based on the financial report for Jun 30, 2024, Basilea Pharmaceutica AG's Cost of Revenue amounts to -34.9m CHF.

What is Basilea Pharmaceutica AG's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-9%

Over the last year, the Cost of Revenue growth was -77%. The average annual Cost of Revenue growth rates for Basilea Pharmaceutica AG have been -13% over the past three years , -9% over the past five years .

Back to Top